# US 2024/0200123 A1 · Systems and methods to detect rare mutations and copy number variation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200123 A1
- Document ID: US20240200123A1
- Status: Published application
- Kind: A1
- Application number: 18/535,812
- Filed: 2023-12-11
- Published: 2024-06-20
- Earliest claimed: 2012-09-04
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: AmirAli TALASAZ; Stefanie Ann Ward MORTIMER
- Web page: https://patentgrep.com/patent/US20240200123A1

## CPC

- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 30/10: Sequence alignment; Homology search
- G16B 30/20: Sequence assembly
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

## Claims

### Claim 1

A method for detecting a presence or an absence of one or more somatic genetic variants in polynucleotides from a sample of a subject, comprising:
(a) tagging a plurality of polynucleotides from a population of polynucleotides obtained or derived from the sample with molecular barcodes to produce tagged parent polynucleotides,
wherein said tagging comprises ligating molecular barcodes to the ends of a polynucleotide molecule from the population of polynucleotides using more than a 10× molar excess of molecular barcodes relative to the polynucleotides in the population of polynucleotides,
wherein at least 20% of the polynucleotides from the population of polynucleotides are attached to molecular barcodes,
(b) amplifying a plurality of the tagged parent polynucleotides to produce progeny polynucleotides;
(c) sequencing at least a subset of the progeny polynucleotides to produce sequencing reads of the progeny polynucleotides;
(d) grouping a plurality of the sequencing reads into a plurality of families using sequence information from at least the molecular barcodes;
(e) generating, from among the sequencing reads in a family, a consensus sequence for each family from among the plurality of families; and
(f) detecting, from among one or more consensus sequences, the presence or the absence of the one or more somatic genetic variants as compared to the reference sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is blood, plasma, serum, tissue or a tumor biopsy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the polynucleotides comprise deoxyribonucleic acid (DNA) molecules, ribonucleic acid (RNA) molecules, complementary DNA (cDNA) molecules, or any combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the population of polynucleotides comprises 100 to 100,000 haploid human genome equivalents of polynucleotides.

### Claim 5 (depends on 1)

The method of claim 1, the polynucleotides in the population are tagged with n different combinations of molecular barcodes, wherein n different molecular barcodes is no more than 100,000*z, wherein z is a mean of an expected number of duplicate molecules in the population of polynucleotides that map to identical start and stop positions on a reference sequence.

### Claim 6 (depends on 5)

The method of claim 5, wherein z is 1 to 10.

### Claim 7 (depends on 6)

The method of claim 6, wherein n different molecular barcodes is no more than 10,000*z.

### Claim 8 (depends on 7)

The method of claim 7, wherein n different molecular barcodes is no more than 1,000*z.

### Claim 9 (depends on 8)

The method of claim 8, wherein n different molecular barcodes is no more than 100*z.

### Claim 10 (depends on 1)

The method of claim 1, wherein the molecular barcode sequences are from 5 to 20 nucleotides in length.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tagging is performed using blunt-end ligation or sticky-end ligation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the ligating comprises using more than an 80× molar excess of molecular barcodes relative to the polynucleotides in the population of polynucleotides.

### Claim 13 (depends on 1)

The method of claim 1, wherein the ligating comprises using more than a 100× molar excess of molecular barcodes relative to the polynucleotides in the population of polynucleotides.

### Claim 14 (depends on 1)

The method of claim 1, wherein at least 40% of the polynucleotides in the population of polynucleotides are attached to molecular barcodes.

### Claim 15 (depends on 14)

The method of claim 14, wherein the polynucleotides in the populations comprise cell-free DNA (cfDNA).

### Claim 16 (depends on 1)

The method of claim 1, further comprising selectively enriching the progeny polynucleotides for target regions associated with cancer prior to the sequencing in (c).

### Claim 17 (depends on 5)

The method of claim 5, further comprising mapping a plurality of the sequencing reads to the reference sequence.

### Claim 18 (depends on 17)

The method of claim 17, wherein the grouping in (d) is further based on at least (1) a start base position of a given sequencing read from among the sequencing reads at which the given sequencing read is determined to start mapping to the reference sequence and/or (2) a stop base position of the given sequencing read at which the given sequencing read is determined to stop mapping to the reference sequence.

### Claim 19 (depends on 1)

The method of claim 1, wherein the one or more somatic genetic variants comprise a single nucleotide variation (SNV), an insertion or deletion (indel), a copy number variation (CNV), or a gene fusion.

### Claim 20 (depends on 1)

The method of claim 1, wherein the one or more somatic genetic variants is an SNV.
